Learn more

RESPONSE GENETICS INC

Overview
  • Total Patents
    152
  • GoodIP Patent Rank
    225,839
About

RESPONSE GENETICS INC has a total of 152 patent applications. Its first patent ever was published in 2001. It filed its patents most often in United States, Israel and China. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are BARRY THOMAS GERARD, PRIMAGEN HOLDING BV and LENZ HEINZ-JOSEF.

Patent filings per year

Chart showing RESPONSE GENETICS INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Danenberg Kathleen D 76
#2 Stephens Craig 21
#3 Danenberg Kathleen 18
#4 Kathleen D Danenberg 11
#5 Kathleen Danenberg 4
#6 Danenberg K D 2
#7 Craig Stephens 2
#8 Anderson Glenda G 1
#9 Maus Martin 1
#10 Stephens Craig C 1

Latest patents

Publication Filing date Title
US2015161327A1 Systems and methods for detecting biological features
WO2013075110A2 A novel eml4-alk variant: primers, probes, methods, and kits for the detection thereof
WO2012097368A2 Her3 and her4 primers and probes for detecting her3 and her4 mrna expression
TW201202703A Primers, probes, methods, and kits for the detection of EML4-ALK variants
AU2011240653A1 KRAS primers and probes
KR20120099630A Methods, primers, probes and kits useful for the detection of braf mutations
EP2173874A2 Methods for isolating long fragment rna from fixed samples
AU2007203027A1 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US2008160517A1 Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
TW200510546A Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus
IL157694A Method of determining dihydropyrimidine dehydrogenase gene expression
CA2439313A1 Method of determining dihydropyrimidine dehydrogenase gene expression
WO0244423A2 Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
IL156272D0 Method of determining a chemotherapeutic regimen based on ercci expression
US6602670B2 Method of determining a chemotherapeutic regimen based on ERCC1 expression
NZ526709A Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
CN101086024A Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
MXPA03004929A Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates.
US6686155B2 Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
US7049059B2 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression